Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes

Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes

Abstract Background Fluvoxamine is one of the selective serotonin reuptake inhibitors (SSRIs) that are regarded as the first-line drugs to manage mental disorders. It has been also recognized with the potential to treat inflammatory diseases and viral infection. However, the effect of fluvoxamine on...

Full description

Bibliographic Details
Main Authors: Yuan Zou, Jing Zhang, Fei Sun, Qianqian Xu, Longmin Chen, Xi Luo, Ting Wang, Qing Zhou, Shu Zhang, Fei Xiong, Wen Kong, Ping Yang, Qilin Yu, Shiwei Liu, Cong-Yi Wang
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Molecular Medicine
Subjects:
Type 1 diabetes
Fluvoxamine
Th1 and Th17 differentiation
Glycolysis
PI3K-AKT signaling
Online Access:https://doi.org/10.1186/s10020-024-00791-1

Internet

https://doi.org/10.1186/s10020-024-00791-1

Similar Items